Bei Liu
Ohio State University
7 Papers
5 Citations
Bei Liu is an academic researcher from Ohio State University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal.
Degang Kong,Degang Kong,Tao Jiang,Tao Jiang,Jian Liu,Xinyi Jiang,Bei Liu,Cheng Lou,Baobing Zhao,Steven L. Carroll,Gong Feng +10 more
TL;DR: Chemoembolization on mice model showed that ATO-microcrystal loaded microspheres, but not ATO, inhibited HCC growth by 60–75%, which indicates ATO within these microsphere gains the chemoembolizing function via the innovative approach.
13
Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma
Yubin Kang,Pasupathi Sundaramoorthy,Cristina Gasparetto,Daniel Feinberg,Shengjun Fan,Gwynn D. Long,E A Sellars,Anderson Garrett,Sascha A. Tuchman,Brandi Reeves,Zhiguo Li,Bei Liu,Besim Ogretmen,Lynn W. Maines,Vered Katz Ben-Yair,Charles D. Smith,Terry F. Plasse +16 more
TL;DR: The first-in-class SK2 inhibitor opaganib is generally safe for administration to RRMM patients, and has potential therapeutic activity in these patients.
9
Migrating Type 2 Dendritic Cells Prime Mucosal Th17 Cells Specific to Small Intestinal Commensal Bacteria
Soo-Mun Ngoi,Yi Yang,Stephen Iwanowycz,Jennifer Gutierrez,Yingqi Li,Christina Williams,Megan Hill,Dongjun Chung,Carter Allen,Bei Liu +9 more
TL;DR: It is identified that the early priming step of commensal-driven Th17 cells is controlled by bona fide Zbtb46-expressing DCs, and early Th17 cell differentiation is initiated by a small subset of migratory DC2s in the gut-draining lymph nodes.
CNPY2 Contributes to Liver Oncogenesis by Promoting UPR-dependent destabilization of p53.
Feng Hong,Ching Ying Lin,Jiejing Yan,Yizhou Dong,Yu-Qi Ouyang,Doyeon Kim,Xiaoli Zhang,Bei Liu,Shaoli Sun,Wei Gu,Zihai Li +10 more
TL;DR: Findings demonstrate that CNPY2 is crucial for liver oncogenesis through the UPR-dependent repression of p53 and activation of oncogenes, providing insights into the design of new therapeutic target for HCC.
6
Redefining CD56 as a biomarker and therapeutic target in Multiple Myeloma.
Francesca Cottoni,Jose Rodriguez,Tiffany Hughes,Nidhi Sharma,Lingna Guo,Gerard Lozanski,Bei Liu,Emanuele Cocucci,Yiming Yang,Don M. Benson +9 more
TL;DR: It is demonstrated that CD56 promotes MM cell growth, and pave the way to novel therapies based on targeting CD56, along with the use of CD56 as a predictive biomarker for MM therapies.
5